New pill xanamem aims to slow Alzheimer's decline

NCT ID NCT06125951

Ongoing Disease control Sponsor: Actinogen Medical Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 22, 2026 · Updated 3 times

Summary

This study tests whether a daily 10 mg pill called Xanamem can safely slow memory and function loss in people with mild or moderate Alzheimer's dementia. About 247 participants will receive either Xanamem or a placebo for 36 weeks, with an option to continue the drug for up to 108 weeks. The main goal is to see if the drug improves scores on a standard dementia rating scale.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Xanamem (a drug taken as a daily pill)
What this could lead to: If successful, Xanamem could become a new daily treatment to slow cognitive and functional decline in early Alzheimer's disease.
What could go wrong: This is a mid-stage trial with only 247 participants, so results may not confirm benefit. The drug is still experimental, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease dementia follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE DEMENTIA, MILD DEMENTIA, MODERATE

Contacts and locations

Locations

ACW Investigative Site 101

Ivanhoe, Victoria, Australia
ACW Investigative Site 102

Kogarah, New South Wales, Australia
ACW Investigative Site 103

Erina, New South Wales, Australia
ACW Investigative Site 104

Nedlands, Western Australia, Australia
ACW Investigative Site 105

Chermside, Queensland, Australia
ACW Investigative Site 106

Darlinghurst, New South Wales, Australia
ACW Investigative Site 107

Macquarie Park, New South Wales, Australia
ACW Investigative Site 108

Malvern, Victoria, Australia
ACW Investigative Site 109

West Perth, Western Australia, Australia
ACW Investigative Site 110

Woodville South, South Australia, Australia
ACW Investigative Site 111

Newcastle, New South Wales, Australia
ACW Investigative Site 112

Parkville, Victoria, Australia
ACW Investigative Site 113

Birtinya, Queensland, Australia
ACW Investigative Site 114

Bedford Park, South Australia, Australia
ACW Investigative Site 115

Carlton, Victoria, Australia
ACW Investigative Site 203

Delray Beach, Florida, 33445, United States
ACW Investigative Site 206

Toms River, New Jersey, 08755, United States
ACW Investigative Site 207

Decatur, Georgia, 30030, United States
ACW Investigative Site 208

Englewood, Colorado, 80113, United States
ACW Investigative Site 209

Sherman Oaks, California, 91403, United States
ACW Investigative Site 210

Dayton, Ohio, 45459, United States
ACW Investigative Site 211

Denver, Colorado, 80218, United States
ACW Investigative Site 212

Portland, Oregon, 97225, United States
ACW Investigative Site 214

Albany, New York, 12208, United States
ACW Investigative Site 215

Bellevue, Washington, 98007, United States
ACW Investigative Site 216

East Providence, Rhode Island, 02914, United States
ACW Investigative Site 217

Independence, Ohio, 44131, United States
ACW Investigative Site 218

Carlsbad, California, 92011, United States
ACW Investigative Site 219

Staten Island, New York, 10314, United States
ACW Investigative Site 220

Austin, Texas, 78757, United States
ACW Investigative site 201

Miami, Florida, 33176, United States
ACW Investigative site 202

New Port Richey, Florida, 34652, United States
ACW Investigative site 204

Orlando, Florida, 32803, United States
ACW Investigative site 205

The Villages, Florida, 32162, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.